摘要
目的探究腹腔积液浓缩腹腔回输联合托伐普坦治疗顽固性腹腔积液的临床治疗效果。方法选取2018年10月—2019年10月在兴国县人民医院就诊的36例顽固性腹腔积液患者为研究对象,按照2:1的比例将全部患者随机分为治疗组24例、对照组12例,对照组采取常规治疗方法(保肝、利尿、人血白蛋白支持等),治疗组在对照组的基础上采取腹腔积液浓缩腹腔回输系统治疗联合托伐普坦治疗。治疗前及治疗后比较两组患者尿量、体质量、钾、钠、钙、氯、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、血清肌酐(Cr)、尿素氮(BUN)指标变化情况。结果治疗后治疗组血钠高于对照组(P<0.05);两组血钙、血氯、血钾比较,差异无统计学意义(P>0.05)。治疗后治疗组体质量低于对照组,尿量多于对照组(P<0.05)。治疗后两组ALT、AST、Cr、BUN比较,差异无统计学意义(P>0.05)。结论对顽固性腹腔积液患者采取腹腔积液浓缩腹腔回输联合托伐普坦的治疗方法能够有效缓解患者症状,增加尿量,值得临床采纳。
Objective To analyze and study the clinical effect of ascites concentrated intrapeRIToneal reinfusion combined with tolvaptan in the treatment of refractory ascites.Methods The subjects of the study were 36 patients with refractory ascites admitted to Xingguo County People's Hospital from October 2018 to October 2019.All patients were randomly divided into two groups according to a ratio of 2:1,with 24 cases in the treatment group and 12 cases in the control group.The control group took the routine Treatment methods(hepatoprotection,diuresis,human albumin support,etc.),the treatment group was treated with ascites concentrated intrapeRIToneal reinfusion system combined with tolvaptan treatment on the basis of the control group.The changes of urine output,body weight,potassium,sodium,calcium,chloride,alanine aminotransferase(ALT),aspartate aminotransferase(AST),serum creatinine(Cr),and urea nitrogen(BUN)indexes were compared between the two groups before and after treatment.Results After treatment,the blood sodium value of the treatment group was significantly higher than that of the control group(P<0.05),and there was no significant difference in blood calcium,blood chlorine,and potassium values between the two groups was small(P>0.05).After treatment,the body weight of the treatment group was significantly lower than that of the control group,and the urine output was significantly higher than that of the control group(P<0.05).After treatment,there was no significant difference in ALT,AST,Cr and BUN between the two groups(P>0.05).Conclusion For patients with refractory ascites,the treatment of ascites concentrated intrapeRIToneal reinfusion combined with tolvaptan can effectively relieve the symptoms of patients and increase urine output,which is worthy of clinical adoption.
作者
李忠东
钟启盛
王素华
Li Zhongdong;Zhong Qisheng;Wang Suhua(Department of Infectious Medicine,Xingguo County People's Hospital,Xingguo 342400,China)
出处
《中国全科医学》
CAS
北大核心
2020年第S02期90-92,共3页
Chinese General Practice
基金
赣州市指导性科技计划项目(GZ2018ZSF617)
关键词
腹腔积液浓缩腹腔回输
托伐普坦
顽固性腹腔积液
治疗结果
Ascites concentrated intraperitoneal reinfusion
Tolvaptan
Refractory ascites
Treatment outcome
